LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.…
LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
LeonaBio (NASDAQ: LONA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 2.020 USD on 20 November 2026, down 47.5% over 52 weeks. Its 52-week range is 1.910 USD to 14.21 USD: the price is 85.8% below the high and 5.8% above the low.
Its market capitalisation is 26.41M USD.
LeonaBio reports return on equity of -380.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 31.85M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.